PDF(Pubmed)
Abstract：
BACKGROUND: CD147, encoded by the BSGgene, has complex transcripts that encode proteins of different lengths. Total BSG transcription is a prognostic biomarker for patients with liver cancer. This study tried to analyze the expression profile and prognostic significance of BSG transcripts in liver cancer.
METHODS: RNA sequencing data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project, survival data from TCGA, and protein expression data from the Human Protein Atlas were systematically analyzed.
RESULTS: Among the four protein-coding transcripts of BSG, ENST00000353555 encoding basigin-2 is the dominant transcript isoform. It might be an independent prognostic biomarker for unfavorable overall survival in patients with liver cancer (HR: 1.404, 95% CI: 1.1224-1.754, p = 0.003).
CONCLUSIONS: ENST00000353555 might be a prognostic biomarker linking unfavorable overall survival in liver cancer patients.
METHODS: RNA sequencing data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project, survival data from TCGA, and protein expression data from the Human Protein Atlas were systematically analyzed.
RESULTS: Among the four protein-coding transcripts of BSG, ENST00000353555 encoding basigin-2 is the dominant transcript isoform. It might be an independent prognostic biomarker for unfavorable overall survival in patients with liver cancer (HR: 1.404, 95% CI: 1.1224-1.754, p = 0.003).
CONCLUSIONS: ENST00000353555 might be a prognostic biomarker linking unfavorable overall survival in liver cancer patients.
摘要：
背景：由BSGgene编码的CD147，有复杂的转录本编码不同长度的蛋白质。总BSG转录是肝癌患者的预后生物标志物。本研究试图分析BSG转录本在肝癌中的表达谱和预后意义。
方法：来自癌症基因组图谱（TCGA）和基因型组织表达（GTEx）项目的RNA测序数据，生存数据来自TCGA，和来自人类蛋白质图谱的蛋白质表达数据进行了系统分析。
结果：在BSG的四种蛋白质编码转录物中，编码basigin-2的ENST00000353555是显性转录物同种型。它可能是肝癌患者不良总生存期的独立预后生物标志物（HR：1.404，95％CI：1.1224-1.754，p=0.003）。
结论：ENST00000353555可能是与肝癌患者不利的总体生存率相关的预后生物标志物。
方法：来自癌症基因组图谱（TCGA）和基因型组织表达（GTEx）项目的RNA测序数据，生存数据来自TCGA，和来自人类蛋白质图谱的蛋白质表达数据进行了系统分析。
结果：在BSG的四种蛋白质编码转录物中，编码basigin-2的ENST00000353555是显性转录物同种型。它可能是肝癌患者不良总生存期的独立预后生物标志物（HR：1.404，95％CI：1.1224-1.754，p=0.003）。
结论：ENST00000353555可能是与肝癌患者不利的总体生存率相关的预后生物标志物。
